Dreams of simple, reliable and scalable processes for the much-hyped cell therapy market have generated demand for cost-effective, GMP-compliant manufacturing methods. The drug-screening market is also hungry for material that will allow the establishment of human cell disease models. A growing number of companies are now trying to coax induced pluripotent stem cells (iPSCs) into specific cells needed for clinical trials. Others are seeking the same goal through direct transdifferentiation protocols. What method will prove superior?
Playing God with the fates of cells
BackgroundDreams of simple, reliable and scalable processes for the much-hyped cell therapy market have generated demand for cost-effective, GMP-compliant manufacturing methods. The drug-screening market is also hungry for material that will allow the establishment of human cell disease models. A growing number of companies are now trying to coax induced pluripotent stem cells (iPSCs) into specific cells needed for clinical trials. Others are seeking the same goal through direct transdifferentiation protocols. What method will prove superior?
Alderaan Biotechnology raise €18.5m in Series A financing
Latest NewsFollowing a €1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised €18.5m in a Series A round led by Advent France Biotechnology and Medicxi.
North Sea Therapeutics raises US$40m in Series B
Latest NewsNorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.
Merck and 4SC collaborate in immunooncology
Latest News4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Merck’s checkpoint blocker avelumab plus 4SC’s HDAC I blocker domatinostat.
The biotech boost – when, if not now?
BackgroundDespite the threat of a looming climate catastrophe, low oil prices and giant industrial conglomerates addicted to fossil resources continue to stifle industrial biotechnology products and innovation. The European Biotechnology Network is now providing a foot up for companies that want to help themselves by launching three very different projects aimed at pushing the bioeconomy forward.
Novo Holdings invest US$12m in AMR companies
Latest NewsMutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Fighting sepsis mortality
Latest NewsCritical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Zelluna: Scientist turns CEO
AppointmentsNorwegian biopharma company Zelluna Immunotherapy appointed erstwhile CSO Namir Hassan as Chief Executive Officer.
Antabio SAS advances cystic fibrosis programme
Latest NewsAntabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Creoptix: New woman at the helm
AppointmentsCreoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, has named Line Stigen Raquet as Chief Executive Officer.